Form 8-K - Current report:
SEC Accession No. 0001564590-20-027622
Filing Date
2020-05-29
Accepted
2020-05-29 16:10:53
Documents
13
Period of Report
2020-05-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dvax-8k_20200528.htm   iXBRL 8-K 69137
2 EX-3.1 dvax-ex31_33.htm EX-3.1 9738
  Complete submission text file 0001564590-20-027622.txt   217840

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dvax-20200528.xsd EX-101.SCH 5772
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20200528_lab.xml EX-101.LAB 20229
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20200528_pre.xml EX-101.PRE 12081
8 EXTRACTED XBRL INSTANCE DOCUMENT dvax-8k_20200528_htm.xml XML 3680
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 20927812
SIC: 2834 Pharmaceutical Preparations